GLP1R and type 2 diabetes mellitus: Due to their cardiorenal benefits, most clinical guidelines recommend SGLT2 inhibitors and GLP-1 RAs as first-line treatment for individuals with type 2 diabetes at very high cardiorenal risk [8–12].